Shilpa Medicare Ltd
Pharmaceuticals & Biotechnology | Small Cap
Shilpa Medicare Ltd operates within the Healthcare Services sector. The company shows mixed financial results. Growth in revenue and operating profit is a positive sign, alongside a strong solvency position. However, there are some concerns with the company's efficiency and liquidity. The company's profitability metrics are generally strong. The company's financial ratios present a mixed picture, with strengths in book value per share but weaknesses in dividend and capital expenditure management. The company's growth shows positive momentum in certain areas but also highlights significant challenges in earnings and net income. Overall, Shilpa Medicare demonstrates a blend of financial strengths and weaknesses that warrant attention.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Overvalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio5.20
- Profitability Ratio9.80
- Efficiency Ratio2.67
- Coverage Ratio7.60
- Solvency Ratio10.00
- Liquidity Ratio4.26
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Shilpa Medicare Ltd operates within the Healthcare Services sector. The company shows mixed financial results. Growth in revenue and operating profit is a positive sign, alongside a strong solvency position. However, there are some concerns with the company's efficiency and liquidity. The company's profitability metrics are generally strong. The company's financial ratios present a mixed picture, with strengths in book value per share but weaknesses in dividend and capital expenditure management. The company's growth shows positive momentum in certain areas but also highlights significant challenges in earnings and net income. Overall, Shilpa Medicare demonstrates a blend of financial strengths and weaknesses that warrant attention.
Overall Valuation Score
P/E RATIO (TTM)
80.24
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
43.86
P/B RATIO
4.13
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
7.06
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
4.09
EV/EBITDA RATIO
23.21
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹545.6 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The growth ratios show a mixed performance. While revenue and operating profit growth rates are strong, earnings per share (EPS) and net income growth rates are negative. This suggests that the company is growing its top line but struggling to convert it into bottom-line profits. The company has been doing well in terms of revenue and operating profit, but not in terms of earnings.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 26.92 | -8.33 | 9.56 | 11.78 | 20.14 |
| Operating Profit Growth Rate | 11.6 | -50.99 | 141.41 | 32.22 | 37.66 |
| Earnings Per Share (EPS) Growth | -61.48 | -153.58 | -198.4 | 117.39 | 211 |
| Asset Growth Rate | 9.27 | 0.97 | 6.51 | 7.05 | 11.93 |
| Net Income Growth Rate | -58.22 | -150.82 | -203.23 | 143.75 | 211.54 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios present a mixed picture. Adjusted and cash earnings per share are at an average level, while the book value per share is strong. However, dividend per share and capital expenditures are low. This suggests that the company has a strong asset base but is not effectively utilizing its capital.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 6.33 | -3.22 | 3.44 | 8.8 | 11.65 |
| Cash Earnings Per Share (Cash EPS) | 15.67 | 7.22 | 15.56 | 19.1 | 18.15 |
| Book Value Per Share | 202.56 | 198.22 | 201 | 237.2 | 129.6 |
| Dividend Per Share (DPS) | 0.56 | 0 | 0 | 0.48 | 0.62 |
| Capital Expenditures (CapEx) | 331 | 226 | 185 | 244 | 358 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability ratios indicate strong performance. Gross profit, return on capital employed, return on equity, return on assets, operating margin, and net margin are all positive. This shows that the company is very profitable.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 10.69 | 0.29 | 11.43 | 15.85 | 20.47 |
| Return on Capital Employed (ROCE) | 6 | 1 | 5 | 8 | 11 |
| Return on Equity (ROE) | 3.35 | -1.74 | 1.77 | 3.29 | 9.38 |
| Return on Assets (ROA) | 7.02 | 3.41 | 7.73 | 9.54 | 11.74 |
| Operating Margin | 17.7 | 9.46 | 20.86 | 24.67 | 28.27 |
| Net Margin | 5.35 | -2.96 | 2.79 | 6.09 | 15.79 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios suggest areas of concern. The fixed asset turnover ratio is low, implying inefficient use of fixed assets. The inventory and receivables turnover ratios are also relatively low. The days sales in inventory and receivable days are high, indicating challenges in managing inventory and collecting receivables. This suggests the company needs to improve its operational processes to enhance efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.85 | 0.76 | 0.83 | 0.9 | 0.75 |
| Inventory Turnover Ratio | 3.04 | 3.09 | 3.05 | 3.11 | 3.42 |
| Receivables Turnover Ratio | 3.78 | 2.95 | 3.2 | 3.08 | 3.21 |
| Days Sales in Inventory Ratio | 120.07 | 118.12 | 119.67 | 117.36 | 106.73 |
| Receivable Days | 96.56 | 123.73 | 114.06 | 118.51 | 113.71 |
| Capital Turnover Ratio | 0.52 | 0.5 | 0.48 | 0.49 | 0.55 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios indicate the company's ability to meet its interest and dividend obligations. While the interest coverage ratio is moderate, the equity dividend coverage ratio is high, showing a strong capacity to cover dividend payments with available equity. This suggests that, the company has the potential to cover the dividend payments.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 3.49 | 0.36 | 1.59 | 2.61 | 6 |
| Equity Dividend Coverage Ratio | 6.25 | 8.33 | 20 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The solvency ratios point to a strong financial position. The debt and debt-to-equity ratios are low, indicating a conservative capital structure. The equity ratio is high, reflecting a solid financial base. Similarly, the debt-to-asset ratio is low, showing that the company has a small proportion of its assets financed by debt. This suggests that the company has been financially stable.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.16 | 0.14 | 0.24 | 0.09 | 0.07 |
| Debt to Equity Ratio | 0.19 | 0.16 | 0.32 | 0.1 | 0.08 |
| Equity Ratio | 0.84 | 0.86 | 0.76 | 0.91 | 0.93 |
| Debt To Asset Ratio | 0.12 | 0.1 | 0.18 | 0.07 | 0.05 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position shows both strengths and weaknesses. While the quick ratio indicates an ability to meet short-term obligations, the current ratio suggests there might be challenges in managing current assets and liabilities. The cash ratio is low, meaning the company may face difficulty in instantly paying off its current liabilities. The operating cash flow ratio is also low, reflecting limited cash generation from operations. The weighted average calculation method was used to assess these ratios.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.42 | 1.01 | 1.32 | 1.47 | 1.26 |
| Quick Ratio | 0.91 | 0.62 | 0.84 | 0.98 | 0.86 |
| Cash Ratio | 0.05 | 0.03 | 0.04 | 0.04 | 0.05 |
| Operating Cash Flow Ratio | 0.15 | 0.22 | 0.19 | 0.19 | 0.37 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 22.22 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 34.17 | Neutral | 369.00 | 19.44 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 37.88 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.12 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 28.36 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Hikal Ltd | 7.13 | -50.15 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 32.71 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | SMS Pharmaceuticals Ltd | 5.94 | 34.36 | Neutral | 171.00 | 9.35 | 102.00 |
| 10 | Shilpa Medicare Ltd | 5.94 | 43.86 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 30.78 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 55.88 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 27.35 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | Aarti Drugs Ltd | 5.07 | 17.33 | Undervalued | 309.00 | 18.54 | 195.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 248.95 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 291.78 | Overvalued | 162.00 | 0.63 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 5.07 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -59.69 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 32.04 | Neutral | 457.00 | 196.94 | 327.00 |
| 21 | Sanofi India Ltd | 3.45 | 18.76 | Neutral | 491.00 | 134.52 | 413.00 |
The management effectiveness of Shilpa Medicare Ltd. presents a mixed picture due to inconsistent financial performance and changes in ownership structure. While the company shows improving sales growth and operating profit margins in recent periods, concerns about profit growth consistency and elevated debt levels persist. The decreased promoter holding also introduces uncertainty regarding long-term strategic alignment.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (2024-2025) | 9.55% - 12.25% | Demonstrates revenue expansion |
| PROS | OPM (2025) | 25% | Reflects operational efficiency |
| CONS | ROCE (2023) | 1% | Indicates inefficient capital use |
| CONS | Promoter Holding (2025) | 44.23% | Raises concerns about ownership alignment |
Financial Performance & Growth
Shilpa Medicare's financial performance shows a mix of positive and negative trends. Sales growth has been inconsistent, but recent trends are positive. The OPM percentage are fluctuating, reflecting operational efficiency variations.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Sales Growth % | 13.88% | 0.84% | 17.60% | -8.35% | 9.55% | 12.25% |
| OPM % | 20.67% | 20.33% | 20.67% | 9% | 21% | 25% |
Capital Efficiency & Returns
Capital efficiency and returns for Shilpa Medicare are weak. The ROCE % have declined significantly over the years, indicating inefficient use of capital.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 17% | 11% | 6% | 1% | 5% | 8% |
Financial Health & Prudence
The financial health and prudence of Shilpa Medicare raise concerns. The debt levels have increased, and the interest coverage ratio has deteriorated.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings | 176 | 208 | 609.67 | 798 | 937 | 588 |
| Interest | 5 | 3.33 | 54.67 | 59 | 92 | 76 |
Shareholding & Ownership Structure
The shareholding and ownership structure of Shilpa Medicare presents mixed signals. The promoter holding has decreased. FII holdings have fluctuated but show some increase in the most recent period. DII holdings have also varied, with a recent increase offsetting previous declines. This mixed pattern suggests cautious optimism among institutional investors.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Promoter Holding % | 53.74 | 51.09 | 50.01 | 50.01 | 44.23 |
| FIIs Holding % | 21.28 | 15.02 | 10.97 | 5.63 | 10.97 |
| DIIs Holding % | 8.74 | 2.18 | 0.54 | 1.65 | 7.55 |
Shilpa Medicare faces moderate risks due to increasing debt and fluctuating profitability. The high cash conversion cycle creates financial vulnerabilities. These factors necessitate active risk management and monitoring.
Segment performance volatility
Shilpa Medicare's quarterly results show variability in sales and profit growth. Sales have ranged from ₹260 Cr to ₹344 Cr, with YOY growth fluctuating from -22.62% to 13.41%. Net profit has varied significantly, from -₹19 Cr to ₹32 Cr, with YOY profit growth ranging from -230% to 1,092%. This volatility indicates potential instability in segment performance.
Foreign exchange or interest rate exposure
The company's interest expenses have increased over the years, particularly in fiscal years 2024 and 2025. Given these trends, it's important to carefully assess the potential impact on Shilpa Medicare's financial stability.
Regulatory compliance cost trends
Employee costs as a percentage of sales have generally increased from 11.87% in 2014 to 22.75% in 2025, indicating rising employee-related expenses. These trends suggest increasing regulatory compliance costs, which could impact profitability.
Accounting quality red flags
Exceptional items fluctuate, impacting profit calculations. Other income contribution to profit before tax (PBT) varies. This can be a cause for concern.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10551.10Bullish
- SMA 20560.19Bearish
- SMA 50549.75Bullish
- EMA 10553.79Bearish
- EMA 20554.25Bearish
- EMA 50550.19Bullish
- DEMA 10551.98Bullish
- DEMA 20555.39Bearish
- DEMA 50559.32Bearish
- TEMA 10550.68Bullish
- TEMA 20553.33Bearish
- TEMA 50555.82Bearish
- MACD0.38Bearish
- ADX23.53Weak Trend
- IndicatorValueSignal
- RSI48.80Neutral
- CCI-57.18Neutral
- ROC 90.17Bullish
- ROC 14-3.58Bearish
- ROC 254.43Bullish
- Stoch K23.23Neutral
- Stoch D24.27Neutral
- IndicatorValueSignal
- BB Upper581.33Neutral
- BB Middle560.19Neutral
- BB Lower539.04Neutral
- ATR8.23Low Volatility
- IndicatorValueSignal
- MFI39.03Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10559.25Bearish
- SMA 20550.46Bullish
- SMA 50545.57Bullish
- EMA 10553.90Bearish
- EMA 20552.43Bullish
- EMA 50541.44Bullish
- DEMA 10553.82Bearish
- DEMA 20556.87Bearish
- DEMA 50563.57Bearish
- TEMA 10551.30Bullish
- TEMA 20554.66Bearish
- TEMA 50560.00Bearish
- MACD2.99Bearish
- ADX27.05Strong Trend
- IndicatorValueSignal
- RSI51.31Neutral
- CCI11.44Neutral
- ROC 9-2.57Bearish
- ROC 144.43Bullish
- ROC 252.07Bullish
- Stoch K43.04Neutral
- Stoch D39.74Neutral
- IndicatorValueSignal
- BB Upper580.66Neutral
- BB Middle550.46Neutral
- BB Lower520.25Neutral
- ATR12.02Low Volatility
- IndicatorValueSignal
- MFI67.64Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10549.12Bullish
- SMA 20549.97Bullish
- SMA 50518.48Bullish
- EMA 10551.09Bullish
- EMA 20544.92Bullish
- EMA 50517.26Bullish
- DEMA 10554.83Bearish
- DEMA 20559.69Bearish
- DEMA 50564.14Bearish
- TEMA 10552.95Bearish
- TEMA 20555.47Bearish
- TEMA 50N/AN/A
- MACD10.25Bearish
- ADX34.46Strong Trend
- IndicatorValueSignal
- RSI55.58Neutral
- CCI15.61Neutral
- ROC 94.41Bullish
- ROC 14-1.22Bearish
- ROC 257.06Bullish
- Stoch K39.90Neutral
- Stoch D44.74Neutral
- IndicatorValueSignal
- BB Upper576.26Neutral
- BB Middle549.97Neutral
- BB Lower523.67Neutral
- ATR18.55Low Volatility
- IndicatorValueSignal
- MFI44.99Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10548.73Bearish
- SMA 20525.89Bullish
- SMA 50467.12Bullish
- SMA 100394.32Bullish
- SMA 200377.41Bullish
- EMA 10544.05Bullish
- EMA 20524.87Bullish
- EMA 50474.08Bullish
- EMA 100428.41Bullish
- EMA 200398.83Bullish
- DEMA 10559.65Bearish
- DEMA 20562.17Bearish
- DEMA 50541.02Bullish
- DEMA 100484.67Bullish
- DEMA 200430.77Bullish
- TEMA 10556.29Bearish
- TEMA 20563.49Bearish
- TEMA 50567.57Bearish
- TEMA 100532.88Bullish
- TEMA 200452.21Bullish
- MACD27.15Bearish
- ADX56.38Strong Trend
- IndicatorValueSignal
- RSI59.66Neutral
- CCI90.05Neutral
- ROC 149.35Bullish
- ROC 2524.32Bullish
- Stoch K71.94Neutral
- Stoch D68.21Neutral
- IndicatorValueSignal
- BB Upper579.48Neutral
- BB Middle525.89Neutral
- BB Lower472.29Neutral
- ATR28.36High Volatility
- IndicatorValueSignal
- MFI79.05Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20397.02Bullish
- SMA 50385.73Bullish
- EMA 20426.32Bullish
- EMA 50390.36Bullish
- DEMA 20479.71Bullish
- DEMA 50419.99Bullish
- TEMA 20522.52Bullish
- TEMA 50429.72Bullish
- MACD45.60Bullish
- ADX38.40Strong Trend
- IndicatorValueSignal
- RSI72.07Overbought
- CCI204.93Overbought
- ROC 1464.14Bullish
- ROC 2568.36Bullish
- Stoch K90.47Overbought
- Stoch D89.68Overbought
- IndicatorValueSignal
- BB Upper553.15Neutral
- BB Middle397.02Neutral
- BB Lower240.90Neutral
- ATR40.95High Volatility
- IndicatorValueSignal
- MFI94.04Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6366.87Bullish
- SMA 12382.06Bullish
- SMA 24376.88Bullish
- EMA 6399.80Bullish
- EMA 12380.63Bullish
- EMA 24354.45Bullish
- DEMA 6431.12Bullish
- DEMA 12403.69Bullish
- DEMA 24405.27Bullish
- TEMA 6459.10Bullish
- TEMA 12406.50Bullish
- TEMA 24410.83Bullish
- MACD51.66Bullish
- ADX24.80Weak Trend
- IndicatorValueSignal
- RSI61.08Neutral
- CCI138.19Overbought
- ROC 2581.32Bullish
- ROC 50150.60Bullish
- Stoch K60.97Neutral
- Stoch D70.01Neutral
- IndicatorValueSignal
- BB Upper496.33Overbought
- BB Middle381.47Neutral
- BB Lower266.62Neutral
- ATR72.60High Volatility
- IndicatorValueSignal
- MFI76.63Neutral